With a growing number of clinical trials testing immune checkpoint inhibitors (ICI) or CAR T therapies, one of the main objectives for researchers now is to extend immunotherapeutic approaches to more patients and tumor types while decreasing the risk of clinical trial failures.
TORONTO (PRWEB)
December 05, 2022
In immuno-oncology, biomarkers are widely used to guide clinical trial programs, help researchers better understand the mechanism of action of their drugs and ultimately give predictive information of drug response or toxicity. However, the complexity associated with drugs’ mechanism of action and the dynamics of the immune response make the ability to analyze biomarkers and extract meaningful insights challenging. It is, therefore, critical to create rich biological databases as tools to reinforce and validate biologic hypotheses, de-risk clinical trial failure and efficiently identify predictive biomarkers. Incorporating a multiomics analysis into drug development can shed light on disease pathways and other complex mechanisms.
Immunotherapy has emerged as the most promising cancer treatment in the last decade with a major impact in oncology by inducing durable responses. However, until now, relatively few patients have been able to benefit from this advance. With a growing number of clinical trials testing immune checkpoint inhibitors (ICI) or CAR T therapies, one of the main objectives for researchers now is to extend immunotherapeutic approaches to more patients and tumor types while decreasing the risk of clinical trial failures.
During this webinar, featured speakers will introduce a reference database in diffuse large B cell lymphoma (DLBCL), a type of non-Hodgkin lymphoma. The ambitious program assesses thousands of parameters using an unsupervised multiomic and multimodal approach. The database may be used to generate maps and clusters that can be used for patient group identification and clinical outcome interpretation.
Register to gain valuable insights about a tumor microenvironment-based multiomics analysis for predictive modelling in biopharma.
Join Mike Mattie, PhD, Director of Translational Sciences and External Collaborations, Kite – a Gilead Company; and Jérôme Galon, PhD, Senior Vice President and Scientific Executive Director, Veracyte, for the live webinar on Friday, December 9, 2022, at 11am EST (4pm GMT/UK).
For more information, or to register for this event, visit A Tumor Microenvironment-Based Multiomics Analysis for Predictive Modelling.
ABOUT XTALKS
Xtalks, powered by Honeycomb Worldwide Inc., is a leading provider of educational webinars to the global life science, food and medical device community. Every year, thousands of industry practitioners (from life science, food and medical device companies, private & academic research institutions, healthcare centers, etc.) turn to Xtalks for access to quality content. Xtalks helps Life Science professionals stay current with industry developments, trends and regulations. Xtalks webinars also provide perspectives on key issues from top industry thought leaders and service providers.
To learn more about Xtalks visit http://xtalks.com
For information about hosting a webinar visit http://xtalks.com/why-host-a-webinar/
Contact:
Vera Kovacevic
Tel: +1 (416) 977-6555 x371
Email: vkovacevic@xtalks.com
Share article on social media or email: